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A B S T R A C T
Cardiovascular disease is a significant cause of morbidity and mortality in patients 
with diabetes mellitus. The impact of tight glycemic control in the mortality has been 
investigated in large randomized clinical trials. The data are controversial, as some 
trials (ACCORD, ADVANCE and VADT) have found that intensive glycemic control 
either has no impact on cardiovascular outcomes or even worsens them. On the other 
hand, results of the 10-year follow-up of the UKPDS study suggest that tight glycemic 
control of younger, newly diagnosed patients with type 2 diabetes may have long-term 
beneficial cardiovascular effects. All these data have led to the adoption of clinical 
guidelines suggesting a different strategy according to the patient’s age and duration 
of diabetes.
I N T R O D U C T I O N
It is well known that patients with diabetes have more than a two – fold increase of 
death rate from cardiovascular disease (CVD) compared to those without diabetes.1 
Adequate glycemic control is considered the cornerstone of the therapeutic strategy 
and the main target of treatment with antidiabetic drugs is to achieve a low value of 
glycated hemoglobin (HbA1c). Several studies and meta – analyses have clearly dem-
onstrated that the lowest risk of CVD was seen in patients with HbA1c <5% while 
the greatest risk was associated with HbA1c >7%.2,3 However, current knowledge 
suggests that hyperglycemia in type 2 diabetes mellitus (T2DM) causes more often 
microvascular complications, such as nephropathy and retinopathy, than macrovas-
cular adverse effects.4 Moreover, the effect of tight glycemic control is less clear on 
macrovascular disease compared to microvascular complications.3,5 New data have 
been added recently about the impact of tight glycemic control in reducing the burden 
of macrovascular complications, especially from the results of the United Kingdom 
Prospective Diabetes Study 10-year post trial monitoring (UKPDS – PTM), which 
enrolled patients with T2DM from the UKPDS cohort.6-8
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AbbreviAtions
ACCORD = Action to Control 
Cardiovascular Risk in Diabetes
ADVANCE = Action in Diabetes 
Vascular Disease-Preterax and 
Diamicron Modified Release 
Controlled Evaluation
CVD = cardiovascular disease
DCCT/EDIC = Diabetes Control and 
Complications Trial/ Epidemiology 
of Diabetes Interventions and 
Complications
HbA1c = glycated hemoglobin A1c
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
UKPDS = United Kingdom Prospective 
Diabetes Study
UKPDS – PTM = United Kingdom 
Prospective Diabetes Study 10 year 
post trial monitoring
VADT = Veterans Affairs Diabetes Trial
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U K P D S  D E S I g N  A N D  P A T I E N T S 
C h A R A C T E R I S T I C S
The original UKPDS trial was designed to evaluate the 
effect of tight glycemic control on the complications of T2DM 
in newly diagnosed patients.4,6,7 About 5102 patients were 
recruited from a total population of 7616 referred patients 
from 1977 to 1991 with fasting plasma glucose more than 108 
mg/dl. Among them, 2514 were excluded since they met vari-
ous exclusion criteria such as ketonuria, chronic renal failure 
(creatinine >2.0 mg/dl), myocardial infarction in the previous 
year, severe illness limiting life expectancy and disinclination 
to accept the rules of the protocol. After a 3 – month dietary 
run – in period only patients with a fasting plasma glucose level 
of more than 108 mg/dl but less than 270 mg/dl were finally 
eligible to participate in the trial. Thus, 3867 patients were 
randomized to receive either conventional glucose control 
(dietary advices from a dietician) or intensive glucose control 
therapy (sulfonylurea or insulin). It must be noted that the 
patients who were overweight (>120% ideal body weight) were 
assigned to receive metformin.6 All these patients were fol-
lowed up in the UKPDS morning clinics every 3 months and 
after 1990 every 4 months. The median follow – up period for 
the sulfonylurea – insulin and metformin groups was 10 and 
10.7 years respectively.6,7 At the end of the study there was a 
borderline non significant reduction (p=0.052) of 16% in the 
relative risk of myocardial infarction in the intensive glucose 
therapy sulfonylurea – insulin group compared to conventional 
therapy. On the other hand, treatment of the overweight pa-
tients with metformin resulted in a significant reduction of the 
risk for myocardial infarction (39%, p=0.001) and death from 
any cause (36%, p=0.001).6 Regarding the microvascular end-
points, a significant risk reduction of about 25% (p=0.0099) 
was noted in the intensively treated group.6
U K P D S  P O S T  T R I A l  1 0 - y E A R 
M O N I T O R I N g
After the completion of the trial on September 30th 1997, 
the investigators decided to continue the follow up of these 
patients for 10 more years in order to gather some additional 
data about the long term effects of intensive glycemic control 
on macrovascular events. A total of 3277 patients (2118 from 
the sulfonylurea – insulin group, 880 from the conventional 
therapy group and 279 from the metformin group) attended 
the UKPDS clinics for the first 5 years. During this period, 
no attempt was made to maintain them in their previous 
therapy arm. Measurements of blood pressure, fasting plasma 
glucose, HbA1c, plasma creatinine and the ratio of albumin 
to creatinine were included in the follow-up. From years 6 
to 10, all patients were assessed only through questionnaires 
every 3 years and this post trial monitoring was successfully 
accomplished on September 30th, 2007. The median follow – up 
periods in the sulfonylurea – insulin and metformin groups 
were 16.8 and 17.7 years respectively.8
The surprising result from this post trial monitoring was 
the significant reductions in myocardial infarction rates and 
in all – cause mortality in both sulfonylurea – insulin (15%, 
p=0.01 and 13%, p=0.007 respectively) and metformin groups 
(33%, p=0.005 and 27%, p=0.002). The authors suggested that 
the benefit of tight glycemic control in patients with T2DM 
extends beyond a definite period of intensive management 
and called this phenomenon a “legacy effect” (or “metabolic 
memory”). Moreover, in the sulfonylurea – insulin group, rela-
tive reductions in risk persisted at 10 years for any diabetes 
– related endpoint (9%, p=0.04), and microvascular disease 
(24%, p=0.001) and risk reductions emerged over time for 
diabetes – related deaths (17%, p=0.01). In the metformin 
group, significant reduction persisted for any diabetes-related 
endpoint (21%, p=0.01) but not for microvascular disease (8%, 
p=0.31) (Table 1). Additionally, no significant reductions were 
observed for stroke and peripheral vascular disease. It must 
be noted that baseline differences in mean HbA1c levels were 
lost within one year of stopping the randomly assigned therapy 
and there were not any significant differences between groups 
in the mean body weight.8
D O E S  T I g h T  g l y C E M I C  C O N T R O l 
P R E v E N T  M A C R O v A S C U l A R  D I S E A S E ?
Data from UKPDS – PTM showed that in patients with 
T2DM, the intensive antidiabetic therapy reduced almost 
15% the risk of myocardial infarction (p=0.01) 10 years after 
the end of the trial. This was observed even though there was 
no difference in HbA1c among the groups one year after the 
end of the study. Similar results emerged from the Diabetes 
Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC), which stud-
ied patients with type 1 diabetes (T1DM). In these patients in-
tensive glucose plasma lowering was associated with significant 
long term beneficial cardiovascular effects and the similarity 
with UKPDS – PTM was the long lasting follow up (about 9 
years) in comparison to other clinical trials.9 Many possible 
explanations have been proposed to interpret these results. A 
plausible explanation is that the long-term intensive therapy 
reduces both hyperglycemia and formation of advanced end 
glycation products.10 However, a recent study clearly showed 
that the contribution of hyperglycemia to cardiovascular risk 
is much greater in T1DM than in T2DM.11 In this trial, a 
1% increase in HbA1c was associated with more than 50% 
increase in cardiovascular risk in patients with T1DM com-
pared to those with T2DM. Moreover, during UKPDS – PTM 
a reduction in the progression of renal disease was observed 
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which had a direct protective effect in the development of 
cardiovascular complications. Supportive to this explanation 
are the recently published data from Steno – 2 study, which en-
rolled patients with T2DM and microalbuminuria and showed 
a significant reduction in cardiovascular risk (p=0.008), after 
a long term follow up of 13 years, in patients who were treated 
with drug combinations for hypertension, dyslipidemia and 
microalbuminuria.12
On the other hand, three large clinical trials with op-
posite results from those of the UKPDS – PTM follow up 
study regarding the impact of intensive glucose therapy on 
cardiovascular mortality were recently published. Although 
ADVANCE (Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evalu-
ation)13 and VADT (Veterans Affairs Diabetes Trial)14 found 
no effect of intensive glucose control on major cardiovascular 
events, ACCORD (Action to Control Cardiovascular Disease 
in Diabetes) showed an increased risk for cardiovascular 
death and total mortality associated with intensive glucose 
control.15 The main features and the hazard ratios of these 
trials additionally to those of UKPDS – PTM are summarized 
in Table 2. All the above three trials similarly concluded that 
good glycemic control did not reduce the major cardiovascu-
lar event rate in short term follow up. Specifically, the AC-
CORD trial was halted in 2008 due to the higher number of 
total and cardiovascular deaths (257 vs. 203, p=0.04) in the 
group randomized to intensive glucose therapy. The authors’ 
opinion was that possible explanations for this unexpected 
result were the rapid reduction in glycated hemoglobin levels 
in both study groups (1.4% in the intensive therapy group 
and 0.6% in the standard-therapy group) within the first 4 
months after randomization, the usage of multiple drugs to 
achieve glucose control, the positive history of cardiovascular 
disease in the majority of participants and the higher rate of 
hypoglycemia in the intensive treatment group. More episodes 
of serious hypoglycaemia (blood glucose <50 mg/dL) requir-
ing medical assistance were found among patients receiving 
the intensive therapy (10%) than among those following the 
standard treatment (3.5%).15 However, among these patients, 
the risk of death was lower in the intensive group compared 
to the standard group.16
One of the basic differences between ADVANCE, AC-
CORD and VADT trials with UKPDS – PTM was that the last 
one had a longer follow up period and the enrolled patients in 
the original UKPDS study were newly diagnosed without se-
vere macrovascular disease history. It is possible that a longer 
follow up period in the ACCORD and ADVANCE trials could 
have led to an improved outcome in the intensive treatment 
group compared to conventional therapy one. Actually, the 
two curves representing macrovascular complications and 
death seem to deviate after about 3 years with a non significant 
decrease in the rate of primary outcome emerging in intensive 
treatment group. This suggests a trend for a possible positive 
result if the trial had longer follow up period.15,17
C U R R E N T  E v I D E N C E - B A S E D 
R E C O M M E N D A T I O N S  I N  C l I N I C A l  P R A C T I C E
On the basis of these large randomized clinical trials, the 
American Diabetes Association (ADA), the American Heart 
Association (AHA) and the American College of Cardiol-
ogy (ACC) jointly published a statement about the intensive 
glycemic control and the prevention of macrovascular and 
cardiovascular disease one year ago.17 The overall impression 
from DCCT and UKPDS – PTM was that intensive glycemic 
control had beneficial cardiovascular effects in T1DM and 
T2DM only after the standard randomization period dur-
ing an extended follow up. Thus, the therapeutic target of 
HbA1c below or around 7% appears to be reasonable in the 
early diagnosed diabetes and it has been associated with long 
term risk reduction of macrovascular disease (ADA, B level 
recommendation, ACC/AHA, class IIb recommendation, 
level of evidence-LOE: A).17 Lowering HbA1c ≤7% has been 
shown to reduce microvascular complications in both T1DM 
and T2DM (ADA, A level recommendation, ACC/AHA, 
Class I recommendation, LOE: A).17 In patients with short 
duration of diabetes, long life expectancy, no hypoglycemic 
episodes and a negative history of significant cardiovascular 
disease, it might be reasonable to achieve HbA1c values closer 
to normal (ADA, B level recommendation, ACC/AHA, class 
IIa recommendation, LOE: C). However, in patients with a 
history of long standing diabetes, advanced macrovascular and 
microvascular complications, severe hypoglycemia episodes 







Soulfonylurea – Insulin group n=2729 n=2118
Any diabetes related end point 12%, p=0.029 9%, p=0.04
Diabetes related death 10%, p=0.34 17%, p=0.01
Death from any cause 5.5%, p=0.44 13%, p=0.007
Myocardial infarction 18%, p=0.052 15%, p=0.01
Metformin group n=342 n=279
Any diabetes related end point 32%, p=0.02 21%, p=0.01
Diabetes related death 42%, p=0.017 33%,p=0.01
Death from any cause 36%, p=0.001 27%, p=0.002
Myocardial infarction 39%, p=0.001 33%, p=0.0.05
UKPDS: United Kingdom Prospective Diabetes Study; UKPDS–
PTM: United Kingdom Prospective Diabetes Study 10-year post trial 
monitoring
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or limited life expectancy, a less tight glycemic control seems 
to be desirable with concomitant use of multiple antidiabetic 
drugs plus insulin.18
C O N C l U S I O N
The main finding of the long-term follow up in UKPDS 
– PTM trial is that tight glycemic control seems to be benefi-
cial if it is achieved in the early stages of T2DM. On the other 
hand, the serious adverse events, such as the hypoglycemias, 
of those treatment strategies would be possible harmful in 
some patients. We need more data from new studies in order 
to enroll all these treatment approaches in our daily clinical 
practice. Until then, all the clinicians have to perform an indi-
vidualized multifactorial intervention in each T2DM patient, 
including treatment with antidiabetic regimens, statins, renin 
– angiotensin blockers and aspirin, since it has been shown 
to reduce the total risk of death and cardiovascular events 
in patients.
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